3D scattering transforms for disease classification in neuroimaging
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2017
- Source ID
- 10.1016/j.nicl.2017.02.004
Entities
People
- Matthan Caan
- Max Welling
- Taco Cohen
- Tameem Adel
Organizations
- AbbVie
- Aidsfonds
- Alzheimer's Association
- Alzheimer's Disease Neuroimaging Initiative
- Alzheimer's Drug Discovery Foundation
- BioClinica
- Biogen
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Canadian Institutes of Health Research
- Chiron Corporation
- Dutch Research Council
- Eisai
- Eli Lilly and Company
- Fonds NutsOhra
- GE HealthCare
- Gilead Sciences
- Hoffmann-La Roche
- Innogenetics
- Janssen Pharmaceuticals
- Johnson & Johnson
- Laboratoires Servier
- Lundbeck
- Merck & Co.
- Meso Scale Diagnostics (United States)
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Netherlands Organisation for Health Research and Development
- Pfizer
- Roche (United States)
- Takeda Pharmaceutical Company
- United States Department of Defense
- ViiV Healthcare